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We determined the activity of adenosine deaminase in normal lymphocytes from peripheral blood, leukemic cells from patients with various hematologic malignancies, and mononuclear cells from kidney-transplant patients, by adapting the method of Hopkinson et al. [Ann. Hum. Genet. 32, 361 (1969) ] to the centrifugal analyzer. Normal lymphocytes separated on Ficoll-Hypaque from peripheral blood had a mean activity of 1.42 u/log cells (SD = 0.57; n = 33). Cells similarly isolated from patients with acute lymphoproliferative and myeloproliferative disease generally showed greater values, but the ranges overlapped. Cells from patients with chronic lymphocytic leukemia had activities that were within or below the normal range. Mononuclear cells isolated from the peripheral blood of 15 stable renal allograft recipients showed a mean activity of 1.90 U/109 cells (SD = 0.59), not significantly different from normal. In contrast, cells from five patients with biopsy-proven allograft rejection showed a mean activity of 12.84 u/log cells (SD = 10.10), which was significantly different from that of the stable patients.
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. normal values #{149} cancer #{149} renal allograft rejection activity in erythrocytes and leukocytes #{149} cytomorphology and activity correlation ADA,' whichcatalyzes the deamination of adenosine to inosine, is a polymorphic enzyme that is found in most human tissues, especially the lymphoid tissues (1) . A possible relationship of this enzyme to the immune system was suggested by reports of its absence from the lymphocytes and erythrocytes of children with combined immunodeficiency disease (2) (3) (4) and quite recently by the apparent reconstitution of immunologic functions in a case with this deficiency, after normal erythrocytes were administered (5). Several investigators have measured the activity of this cytoplasmic enzyme in purified suspensions of normal human lym-phocytes, and from a variety of hematologic neoplasms (5) (6) (7) (8) (9) . Tung et al. (8) reported low ADA activity in cells from chronic lymphocytic leukemia patients. Meier et al. (6) and Smyth and Harrap (7) reported high activity in cells from acute myelogenous leukemia and acute lymphocytic leukemia patients, as well as chronic myelogenous leukemia patients during blast crisis. These two groups of workers, however, came to opposing conclusions concerning the usefulness of ADA measurement in distinguishing between the lymphocytic and myelogenous leukemias.
Increase in ADA activity has also been reported in mixed lymphocyte culture and after the stimulation of lymphocytes with phytohemagglutinin and pokeweed mitogen (10) . The increase in activity precedes DNA synthesis and may be related to the need for proliferating cells to maintain a low concentration of adenosine, an inhibitor of cell division.
In this investigation, we used the centrifugal analyzer to measure the ADA activity of normal lymphocytes, leukemic cells, and mononuclear cells from kidneytransplant patients. The investigation was prompted by (a) the need for further investigation of the clinical usefulness of ADA in distinguishing between various types of hematologic malignancy and (b) preliminary observations in our laboratory that the assay of ADA activity in mononuclear cells isolated from the blood of kidney transplant patients coincides with, and may predict, graft rejection. Although not dealt with in this investigation, a third reason is the need for a rapid method of ADA assay, for studying the polymorphic forms of the enzyme, the mechanism by which they arise, and their relationship to cell proliferation and the immune response (1, (11) (12) (13) (14) . 
Materials and Methods Reagents

Patients
Thirty-seven patients who had peripheral blood involvement with various hematologic malignancies were studied before initial or reinduction chemotherapy (Table 4 ). Malignant cells for ADA assay were isolated from blood within one day of diagnosis by peripheral blood and bone marrow examination.
Similarly, a mononuclear-cell enriched preparation of peripheral blood leukocytes was obtained from 15 renal allograft recipients. An additional five allograft recipients with biopsy-proven rejection were also studied for leukocyte ADA activity before the start of anti-rejection therapy.
Preparation of Cell Suspension
Normal lymphocytes and leukemic cells were separated from peripheral blood collected in ethylenediaminetetraacetate by the Ficoll-Hypaque method described by Boyum (15) . Cells were washed three times in phosphate-buffered saline and suspensions were made containing 5 X 106 to 20 X 106 cells per milliliter of phosphate-buffered saline. Wright-Giemsa-stained smears of the cell suspensions were prepared and examined for purity. Because monocyte contamination of normal controls was less than 5%, and less than 1% in patients with hematologic malignancies, no effort was made to remove this cell type. Suspensions were kept frozen in phosphate-buffered saline at -20 #{176}C, at which temperature they were stable for a minimum of two weeks. Suspensions of mononuclear cells from the peripheral blood of renal allograft recipients were isolated in the transplantation laboratory according to a modification of the method described by Singal et al. (16) . Less than 1% granulocyte contamination was noted and no attempt was made to differentiate lymphocytes from monocytes in the final preparation.
Before assay of ADA activity, the cells were ruptured by thawing and freezing three times, and then centrifuged at 2000 X g for 10 mm. ADA activity was assayed on 25 to 100 tl of the clear suspernatant fluid, depending on the cell count of the suspension.
ADA Assay
ADA activity was assayed kinetically by a coupled enzymatic system, as follows:
Nucleoside phosphorylaseand xanthine oxidase are present inexcess in the reaction mixture, so that the rate of formation of the end product, uric acid, is an indirect measure ofADA activity. The reaction mixture has a total volume of 500 zl and contains 1.0 mol of adenosine, 0.03 U of xanthine oxidase, 0.06 U of nucleoside phosphorylase, 0.04 mmol of phosphate buffer, pH 7.1, and 25-100 il of the cell extract containing 0.4 to 4 mU of ADA. Formation of uric acid is monitored at 293 nm and 37 #{176}C with a centrifugal analyzer (GEMSAEC; Electronucleonics Inc., Fairfield, N.J.). A unit of ADA activity is defined as the enzyme activity that catalyzes the conversion of 1 mol of adenosine to uric acid in 1 mm at 37 #{176}C. At 293 nm, the molar absorptivity of uric acid is 12.5 X 10 liter mo11 cm1. Because the GEM-SAEC centrifugal analyzer was designed essentially to be operated at wavelengths above 300 nm, the absorbances of uric acid standards on the centrifugal analyzer were checked at 293 nm against a precalibrated Gilford 2000 spectrophotometer with Beckman DU optics. As shown in Figure 1 , a straight line was obtained on both instruments, but the absorbances on the centrifugal analyzer were slightly lower and corresponded to a molar absorptivity of 11.5 X 10 liter mol' cmt. In view of the obvious advantages of the centrifugal analyzer, this discrepancy was corrected for by using the value 11.5 X 10 for the molar absorptivity.
Results Figure 2 shows the relation between time and ab- sorbance for ADA from calf intestine at an activityof 1.6 mU per 0.5 ml of incubation mixture. After a slight initial lag period, the absorbance change with time becomes constant. The lag period is about 80 s, and therefore the schedule routinely used to assay for ADA was to make an initial absorbance reading at 120 s, followed by seven readings at 40-s intervals. A standard curve for the assay of ADA from calf intestine is shown in Figure 3 . The rate of reaction vs. ADA activity is linear up to 4 mU per 0.5 ml of incubation mixture; samples with greater ADA activity were diluted and reassayed.
Precision
The precision of ADA assay was determined on purified ADA from calf intestine, asshown in Table 1 . The CV for intradisk or within-run determinations on 13 samples was 0.9% at 0.8 mU of ADA percuvetteand
1.1% at 1.6 mU. For the interdisk variation, 21 samples were tested during 28 days. The CV was 4.4% at the lower ADA activity and slightly less (3.8%) at the higher activity. The precision of ADA assay was also determined for the Gilford Model 2000 spectrophotometer. The run-to-run CV on 14 samples at 1.6 mU/cuvette was very similar to that obtained for the interdisk variation on the centrifugal analyzer (4.2%).
Normal Values
ADA activity was measured in lymphocytes from 33 blood-bank donors ( Table 2) . The mean activity, 1.42 U/10 cells (SD = 0.57), did not differ significantly between men and women. ADA activity was also determined on washed erythrocytes from 35 donors, without separation of the leukocytes. The mean ADA activity was 23 mU/109 cells (SD = 10). Extracts of the lymphocytes from nine normal laboratory personnel were also run simultaneously on the centrifugal analyzer and the Gilford 2000. As shown in Table 3 , the correlation was good (r = 0.978, slope = 1.03).
Leukemic Patients
The results for the ADA activities from the leukemic cells of 37 patients with hematologic malignancies are listed in Table 4 and graphically represented in Figure  4 . Activities in the lymphoproliferative diseases varied from less than normal to markedly above normal and roughly paralleled the degree of cytologic differentiation of the malignancy. Except for one case, patients with chronic lymphocytic leukemia, a well-differentiated lymphoproliferative disorder, tended to have values that were lower than the mean normal value for ADA activity. Two patients with prolymphocytic leukemia, a less-differentiated and more aggressive subtype of chronic lymphocytic leukemia (17) , had normal and above-normal activities, respectively. Of three patients with the leukemic phase of poorly differentiated lymphocytic lymphoma, two had supranormal values and Patients with acute myeloproliferative diseases generally showed supranormal ADA activity, and values appeared to correlate best with monocytoid differentiation. In the three cases with acute myelomonocytic leukemia and the two cases with acute monoblastic leukemia the ADA activity exceeded that in eight of the nine cases with acute myelogenous leukemia. Patients with chronic myelogenous leukemia in blast crisis had higher values than those found in patients with acute myelogenous leukemia, but the values overlapped with those for patients with acute myelomonocytic leukemia and acute monoblastic leukemia.
Transplant Patients
Mononuclear cells from kidney transplant patients were isolated in the transplantation laboratory by a technique that differed slightly from that used in ours. However, ADA activities of normal lymphocytes isolated by this technique yielded a mean of 1.62 U/b9 cells (Table 5) , which is very similar to that of our control group (1.42 U/b9 cells; Table 2 ).
ADA activity was determined on extracts of mononuclear cells from three groups of patients. Groups I and II included 15 patients who had functioning allografts, with a mean serum creatinine of 14 mg/liter (SD = 3). Group I included seven patients with long-term graft survival (4±0.9 years) and stable immunosuppression (1.2-2.5 mg of azathioprine per kilogram body wt per day). Group II included eight patients who were in less-stable condition, because they were either early post-transplant patients (<10 months), or on varying doses of azathioprine (<0.4 mg/kg/day) because of signs of intolerance in the bone marrow. Group III included five patients who were undergoing acute graft rejection, verified by percutaneous needle biopsy. As shown in Table 5 , the mean ADA activity of Groups I and II combined was 1.90 U/b9 cells, not appreciably different from the control group. However, the mean for Group I was 1.34 U/b9 cells, which is significantly (P <.02) different from that of Group 11(2.40 U/b9 cells). Group III had a mean value of 12.84 U/b9 cells, also significantly (P <.02) different from that of Groups I and
"-
Discussion
Current interest in evaluating the immunologic characteristics of lymphoid malignancies has evoked a corresponding interest in studying enzymes with appreciable activities in lymphoid cells. In this investigation, a rapid method was developed to assay for ADA, an enzyme with an increasingly evident relation to the immune system.
Because uric acid is the end product of purine metabolism in man, an assay for ADA based on the rate of formation of uric acid offers two advantages. First, the possibility that uric acid is further altered by enzymes(s) in the cell extract under study is eliminated-an obvious advantage over another method used by some workers in which ADA activity is measured by monitoring the rate of decrease in the absorbance of adenosine at 265 nm as it is converted to inosine (6) . Second, if required, the method may be used to assay for two other two enzymes of purine catabolism, the nucleoside phosphorylases and xanthine oxidase, by making them the ratelimiting enzymes in the coupled reaction system.
Our results on leukemic cells are in agreement with those of Meier et al. (6) in that a separation of the various morphologic types of leukemia on the basis of ADA content is not feasible. It is possible, however, that an examination of the polymorphic patterns of ADA by starch-gel electrophoresis or chromatography, in addition to the determination of ADA, may prove clinically useful. Studies of this type are currently under way in our laboratory.
Another interest in our laboratory was to determine whether the method would aid in identifying those patients with chronic myelogenous leukemia in blast crisis who may respond to therapy designed for acute lymphocytic leukemia, since it is generally recognized that approximately one third of the cases of chronic myelogenous leukemia in blast crisis show blasts with the cytologic features of lymphoblasts (18) .
Of the four patients with chronic myelogenous leukemia in blast crisis that we studied, the cells of only one patient had those features. The ADA activity of these cells was 5.7 U/b9 cells, an intermediate value for the patients in this group (Table 4) .
Cells from patients with lymphoproliferative disease showed an inverse relationship of ADA activity to cytologic differentiation.
Chronic lymphocytic leukemia, a well-differentiated lymphocytic proliferation, was characterized by low-normal ADA activity, while prolymphocytic leukemia, poorly differentiated lymphocytic lymphoma, and acute lymphocytic leukemia, which are progressively less differentiated, showed higher values. An interesting correlation of ADA activity with cytomorphology was also noted in patients with acute myeloproliferative disorders. In this group, the ADA activity was increased in patients whose cells showed monocytoid differentiation.
These results are consistent with the observations of Fischer et al. (14) that peripheral blood monocytes incubated in vitro show a several-fold increase in ADA activity upon maturation to macrophages, an increase accompanied by an increase in the activity of the monomeric form of the enzyme, and a gradual shift from the polymeric to the monomeric form (14) .
Our preliminary results on kidney-transplant patients strongly suggest that determination of ADA activity in mononuclear cells isolated from peripheral blood can be useful in confirming the clinical diagnosis of allograft rejection, and may indicate excessive immunosuppression with a low ADA activity before complications with infectious disease arise. Current methods of immunologic monitoring of immunosuppressed allograft recipients rely primarily on cell and serologic assays, which are time consuming, frequently requiring more than one day to perform. In our laboratory, it is possible to isolate mononuclear cells from as many as 10 patients and determine their ADA activity within a day. This is of definite advantage in monitoring renal allograft recipients.
